PALO ALTO, California – KORTUC INC., a clinical-stage biotechnology company pioneering a novel radiosensitizer for the treatment of radioresistant tumors, today announced the successful close of a $5 million initial tranche of its Series B equity financing, completed on June 30, 2025. The financing was led by Midas Capital, a Japanese private equity firm with participation from new investors.
Proceeds from the Series B round will support KORTUC’s ongoing registrational clinical trial in breast cancer and the launch of additional clinical trials for cervical and rectal cancers. The company’s next major milestone is the release of the first controlled dataset from its breast cancer trial, conducted in the UK and India, expected in early 2027.
“This milestone reflects growing global confidence in KORTUC’s innovative approach to overcoming tumor hypoxia—one of the fundamental challenges in radiation oncology,” said Kazu Matsuda, Chief Executive Officer of KORTUC INC. “Our goal is to redefine conventional radiotherapy as the standard of care for patients with treatment-resistant cancers. This funding ensures we stay on track to deliver controlled clinical data and accelerate our global commercialization plans.”
KORTUC’s injectable radiosensitizer is designed to enhance the effect of radiotherapy by targeting hypoxic tumor environments, which are a major cause of radiotherapy resistance. The product has already been studied in more than 1,000 patients for various types of solid tumor in Japan and is currently being evaluated in a registrational Phase II trial led by the Institute of Cancer Research (ICR) in partnership with major cancer centers across the UK and India. Additional clinical trials are being planned in the U.K., France, India, Thailand as well as the U.S..
About KORTUC
KORTUC Inc. is a U.S.-based oncology biotechnology company headquartered in Palo Alto, California. Originally founded in Japan, KORTUC is focused on overcoming tumor hypoxia to improve the effectiveness of radiotherapy for solid tumors. With a proprietary radiosensitizer and global clinical collaborations, the company aims to make effective, affordable, and accessible cancer therapies available to patients worldwide.
For more information, please visit https://kortuc.com/